EGFR and head and neck squamous cell carcinoma: In addition to monoclonal antibodies, several researchers focused on small molecules, such as tyrosine kinase inhibitors (TKIs) of EGFR, which are ineffective in HNSCC, although early results from other trials with combination therapies were promising.